Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesCingulate Inc

Cingulate Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
4.38 USD 0.12 ( 2.82%)
Last update at 2026-11-09T18:16:00Z
VOLUME
26455
Market Cap
74.31M

Momentum Score

…

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.26
Low
4.42
High
52 Week Price Range
3.16
Low
11.89
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cingulate Inc (CING) is a NASDAQ-listed company with limited public disclosures, so its core business is not clearly described. Meaningful assessment of long-term growth drivers is not possible; investors may view the stock as speculative pending clearer filings, strategic updates or evidence of sustainable operations.

Key risks include limited transparency, unclear or undeclared revenue sources, potential illiquidity and high share-price volatility, plus execution and financing risk if the company needs capital to implement any future plans.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.26
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-8.52M
Debt / Equity
3.50
ROE
-198.74%
Net Debt
-2.17M
ROCE
-418.81%
Diluted EPS TTM
-3.55

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -22.45M -15.55M -23.53M -17.68M -20.71M
Net income -22.45M -15.55M -23.53M -17.85M -20.74M
Selling general administrative 10.16M 6.20M 7.27M 8.51M 12.27M
Selling and marketing expenses - - 0.58M - -
Gross profit -0.54M -0.65M -0.58M - -
Reconciled depreciation 0.54M 0.65M 0.50M 0.39M 0.71M
Ebit -19.94M -15.55M -23.53M -17.90M -20.68M
Ebitda -19.40M -14.89M -22.95M -17.50M -19.97M
Depreciation and amortization 0.54M 0.65M 0.58M 0.39M 0.71M
Operating income -19.94M -15.64M -22.76M -17.50M -20.68M
Other operating expenses 19.94M 15.64M 22.76M 17.50M 20.68M
Interest expense 0.92M 0.10M 0.78M 0.17M -0.03M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -1.36M 0.10M -0.77M -0.17M -0.03M
Income tax expense - -0.00M 0.00M 0.17M 0.03M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 19.40M 14.99M 22.18M 17.50M 20.68M
Cost of revenue 0.54M 0.65M 0.58M - -
Total other income expense net -2.51M 0.10M -0.78M -0.17M -0.03M
Net income from continuing ops -22.45M -15.55M -21.21M -17.68M -20.71M
Net income applicable to common shares - - - -17.68M -20.71M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 15.07M 14.86M 3.49M 11.41M 22.89M
Other current assets 0.99M 0.42M 0.33M 2.18M 2.39M
Total liab 12.56M 7.41M 10.36M 7.52M 2.04M
Total stockholder equity 2.51M 7.46M -6.87M -69.41M 20.84M
Other current liab 1.74M 0.84M 1.65M 1.23M 0.30M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M - 0.00M 0.00M
Retained earnings -132.38M -108.49M -92.94M -69.41M -51.73M
Other assets - -17412.80M 0.00M - -
Cash 10.95M 12.21M 0.05M 5.36M 16.49M
Total current liabilities 10.31M 4.97M 10.23M 7.01M 1.18M
Current deferred revenue - - - - 0.60M
Net debt -2.17M -7.11M 3.46M 0.17M -15.61M
Short term debt 6.53M 2.66M 3.38M 5.02M 0.02M
Short long term debt 6.30M 2.53M - 5.00M -
Short long term debt total 8.79M 5.10M 3.51M 5.53M 0.88M
Other stockholder equity 134.88M 115.94M 86.07M -0.00M 72.57M
Property plant equipment - - - 3.54M 4.00M
Total current assets 11.95M 12.66M 0.40M 7.87M 18.88M
Net tangible assets - - - 3.88M 3.08M
Short term investments - - - 0.00M 0.00M
Net receivables 0.01M 0.03M 0.01M 0.23M 0.69M
Long term debt 1.15M 2.44M - - -
Inventory - -0.05M - 0.10M -0.69M
Accounts payable 2.04M 1.27M 5.20M 0.76M 0.26M
Accumulated other comprehensive income - - - - 0.00M
Non currrent assets other - 17412.80M -13194.39M -5906.40M -1357.94M
Non current assets total 22582.68M 2.20M 3.09M 3.54M 4.00M
Capital lease obligations 1.34M 0.14M - 0.53M 0.88M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.21M -0.18M -0.15M -0.81M
Change to liabilities - - - 0.79M -1.32M
Total cashflows from investing activities -0.16M -0.21M -0.22M -0.15M -0.81M
Net borrowings 6.00M 4.95M 2.98M 4.98M -0.94M
Total cash from financing activities 16.15M 30.82M 9.95M 4.90M 26.54M
Change to operating activities - - - -0.65M -1.35M
Net income -22.45M -15.55M -23.53M -17.68M -20.71M
Change in cash -1.26M 12.16M -5.30M -11.14M 15.30M
Begin period cash flow 12.21M 0.05M 5.36M 16.49M 1.20M
End period cash flow 10.95M 12.21M 0.05M 5.36M 16.49M
Total cash from operating activities -17.25M -18.45M -15.03M -15.88M -10.43M
Issuance of capital stock 10.15M 25.88M 6.15M 0.00M 20.37M
Depreciation 0.54M 0.65M 0.58M 0.39M 0.71M
Other cashflows from investing activities 0.00M -0.21M 0.00M -0.00M -0.00M
Change to account receivables 0.02M -0.01M 0.22M 0.46M -0.54M
Other cashflows from financing activities -0.00M 30.82M 3.00M 4.91M 7.10M
Change to netincome - - - 0.80M 12.78M
Capital expenditures 0.16M 0.21M 0.22M 0.15M 0.81M
Change in working capital 0.83M -4.55M 7.10M 0.60M -3.21M
Stock based compensation 1.52M 1.00M 0.81M 0.80M 12.78M
Other non cash items 3.83M 1.00M -27.76M - -22.49M
Free cash flow -17.41M -18.66M -15.26M -16.04M -11.25M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
CING
Cingulate Inc		 0.12
2.82%		 4.38 - - - 3.18 -0.36
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Cingulate Inc

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

1901 West 47th Place, Kansas City, KS, United States, 66205

913 942 2300

https://www.cingulate.com

14

Name Title Year Born
Dr. Shane J. Schaffer Pharm.D., PharmD CEO & Chairman 1975
Mr. Louis G. Van Horn CPA, M.B.A. Exec. VP & CFO 1959
Dr. Laurie A. Myers M.B.A., Ph.D. Exec. VP & COO 1957
Mr. Craig S. Gilgallon Esq. Exec. VP, Gen. Counsel & Board Sec. 1973
Dr. Raul R. Silva M.D. Exec. VP & Chief Science Officer 1958
Thomas Dalton Head of Investor & PR NA
Dr. Matthew N. Brams M.D. Exec. VP & Chief Medical Officer 1964
Dr. Shane J. Schaffer Pharm.D., PharmD CEO & Chairman of the Board 1975
Dr. Laurie A. Myers M.B.A., Ph.D. Executive VP & COO 1957
Dr. Matthew N. Brams M.D. Executive VP & Chief Medical Officer 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…